亚宝药业(600351.SH)：西格列汀二甲双胍缓释片取得药品注册证书

Core Viewpoint - The company, Yabao Pharmaceutical (600351.SH), announced that its wholly-owned subsidiary, Beijing Yabao Biopharmaceutical Co., Ltd., has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new diabetes treatment [1]. Group 1 - The drug Sitagliptin Metformin Extended-Release Tablets is intended for adult patients with type 2 diabetes who are currently receiving a combination treatment of Sitagliptin and Metformin Extended-Release Tablets [1].